TLP
BMRN icon

Tri Locum Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Tri Locum Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,100
Closed -$1.36M – 54
2022
Q4 		$1.36M Buy
+13,100
New +$1.23M 0.55% 33

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Tri Locum Partners's BMRN Position: Q2 2023 in Review

Tri Locum Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 76,070 shares — an estimated $7.4M sold.

Tri Locum Partners first reported a position in BMRN in Q4 2022 and held it in 2 quarters. The position peaked at $12.9M in Q4 2022. 559 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

  • Tri Locum Partners reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Tri Locum Partners sold 76,070 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $7.4M.
  • Tri Locum Partners first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Tri Locum Partners's BioMarin Pharmaceuticals position peaked at $12.9M in Q4 2022.
  • 559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Tri Locum Partners's 13F filing for Q2 2023, filed 14 Aug 2023.